Nadia Alatrakchi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C, Chronic | 8 | 2023 | 1032 | 1.570 |
Why?
|
Hepacivirus | 10 | 2023 | 1336 | 1.060 |
Why?
|
Hepatitis B, Chronic | 4 | 2024 | 410 | 0.850 |
Why?
|
Hepatitis C | 6 | 2023 | 1584 | 0.770 |
Why?
|
Liver Cirrhosis | 5 | 2022 | 1935 | 0.630 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 283 | 0.560 |
Why?
|
CD8-Positive T-Lymphocytes | 9 | 2023 | 4580 | 0.540 |
Why?
|
Hepatic Stellate Cells | 2 | 2016 | 119 | 0.520 |
Why?
|
Macrophage Activation | 1 | 2018 | 553 | 0.500 |
Why?
|
Interleukin-10 | 3 | 2017 | 1175 | 0.430 |
Why?
|
Transforming Growth Factor beta | 2 | 2012 | 1961 | 0.400 |
Why?
|
HIV Infections | 10 | 2024 | 17351 | 0.400 |
Why?
|
Hepatitis B virus | 3 | 2024 | 528 | 0.400 |
Why?
|
Immunity, Cellular | 2 | 2015 | 1560 | 0.360 |
Why?
|
Th1 Cells | 3 | 2006 | 1036 | 0.340 |
Why?
|
Interferon-gamma | 6 | 2017 | 3162 | 0.320 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 2822 | 0.320 |
Why?
|
Liver | 7 | 2024 | 7529 | 0.320 |
Why?
|
Hepatitis, Viral, Human | 1 | 2009 | 141 | 0.310 |
Why?
|
Antigens, CD | 1 | 2018 | 4003 | 0.300 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2012 | 3080 | 0.280 |
Why?
|
Antiviral Agents | 5 | 2023 | 3060 | 0.280 |
Why?
|
HIV-2 | 1 | 2006 | 156 | 0.250 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2005 | 621 | 0.220 |
Why?
|
Interferon-alpha | 3 | 2019 | 921 | 0.220 |
Why?
|
T-Lymphocytes | 4 | 2013 | 10194 | 0.220 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2010 | 1897 | 0.200 |
Why?
|
Lamivudine | 1 | 2003 | 366 | 0.200 |
Why?
|
Ribavirin | 1 | 2004 | 395 | 0.200 |
Why?
|
HIV-1 | 5 | 2010 | 6863 | 0.190 |
Why?
|
HIV Long-Term Survivors | 1 | 2002 | 121 | 0.190 |
Why?
|
Antigens, CD1d | 2 | 2013 | 228 | 0.190 |
Why?
|
Natural Killer T-Cells | 2 | 2017 | 322 | 0.180 |
Why?
|
Interleukin-2 | 2 | 2017 | 1889 | 0.180 |
Why?
|
T-Lymphocyte Subsets | 3 | 2017 | 1802 | 0.180 |
Why?
|
Hepatocytes | 3 | 2021 | 1233 | 0.180 |
Why?
|
HIV | 2 | 2018 | 1582 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2005 | 4369 | 0.170 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2002 | 662 | 0.150 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 687 | 0.150 |
Why?
|
Complementarity Determining Regions | 1 | 1998 | 149 | 0.150 |
Why?
|
Virus Replication | 1 | 2005 | 2435 | 0.140 |
Why?
|
ras GTPase-Activating Proteins | 1 | 2016 | 94 | 0.130 |
Why?
|
Interferons | 1 | 2019 | 706 | 0.120 |
Why?
|
Anti-Retroviral Agents | 1 | 2005 | 1784 | 0.120 |
Why?
|
Immunologic Memory | 1 | 2021 | 1359 | 0.120 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2449 | 0.110 |
Why?
|
Fatty Acids | 1 | 2021 | 1808 | 0.110 |
Why?
|
Lymphocyte Count | 2 | 2006 | 778 | 0.110 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2012 | 145 | 0.100 |
Why?
|
Viral Core Proteins | 1 | 2012 | 161 | 0.100 |
Why?
|
Hepatitis B | 2 | 2024 | 705 | 0.090 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1998 | 1374 | 0.090 |
Why?
|
Transcriptional Activation | 1 | 2016 | 1756 | 0.090 |
Why?
|
Pyrrolidinones | 1 | 2010 | 116 | 0.090 |
Why?
|
Collagen Type I | 1 | 2012 | 616 | 0.080 |
Why?
|
Anti-HIV Agents | 2 | 2010 | 4527 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 2 | 2024 | 1118 | 0.080 |
Why?
|
Cytomegalovirus Infections | 2 | 2006 | 831 | 0.080 |
Why?
|
Humans | 27 | 2024 | 761504 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 3810 | 0.070 |
Why?
|
Viremia | 1 | 2010 | 707 | 0.070 |
Why?
|
Cell Division | 2 | 2006 | 4465 | 0.070 |
Why?
|
Adult | 13 | 2024 | 221177 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 1640 | 0.070 |
Why?
|
Viral Load | 3 | 2010 | 3332 | 0.070 |
Why?
|
RNA, Viral | 2 | 2006 | 2846 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2019 | 3065 | 0.070 |
Why?
|
Middle Aged | 13 | 2024 | 220895 | 0.070 |
Why?
|
Disease Progression | 3 | 2021 | 13506 | 0.060 |
Why?
|
Male | 14 | 2024 | 360804 | 0.060 |
Why?
|
Gene Products, gag | 1 | 2006 | 312 | 0.060 |
Why?
|
Female | 15 | 2024 | 392644 | 0.060 |
Why?
|
Galactosylceramides | 2 | 2017 | 92 | 0.060 |
Why?
|
Zambia | 1 | 2024 | 262 | 0.060 |
Why?
|
Macrophages | 1 | 2018 | 5769 | 0.050 |
Why?
|
Aged | 9 | 2019 | 169289 | 0.050 |
Why?
|
Lymphocyte Activation | 3 | 2017 | 5486 | 0.050 |
Why?
|
Immunotherapy | 1 | 2017 | 4652 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2005 | 988 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 1998 | 5146 | 0.040 |
Why?
|
Gene Expression | 1 | 2012 | 7581 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2021 | 523 | 0.040 |
Why?
|
2-Naphthylamine | 1 | 2019 | 20 | 0.040 |
Why?
|
Immunoglobulin alpha-Chains | 1 | 1998 | 8 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2006 | 1844 | 0.040 |
Why?
|
Macrocyclic Compounds | 1 | 2019 | 68 | 0.040 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 1998 | 71 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5709 | 0.040 |
Why?
|
Young Adult | 3 | 2024 | 59243 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2012 | 26125 | 0.040 |
Why?
|
NF-kappa B | 2 | 2016 | 2490 | 0.040 |
Why?
|
Mucin-1 | 1 | 2002 | 540 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2004 | 2571 | 0.040 |
Why?
|
Viral Proteins | 1 | 2005 | 1804 | 0.040 |
Why?
|
Uracil | 1 | 2019 | 207 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2019 | 432 | 0.040 |
Why?
|
Lactams, Macrocyclic | 1 | 2019 | 318 | 0.040 |
Why?
|
Proline | 1 | 2019 | 457 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2003 | 1784 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2023 | 2020 | 0.030 |
Why?
|
Fibrosis | 1 | 2022 | 2049 | 0.030 |
Why?
|
Epitopes | 1 | 2021 | 2503 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 800 | 0.030 |
Why?
|
Chemokines | 1 | 2019 | 960 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2017 | 819 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1787 | 0.030 |
Why?
|
Interleukin-4 | 1 | 2017 | 1149 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1341 | 0.030 |
Why?
|
Chronic Disease | 1 | 2007 | 9318 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2007 | 18965 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2018 | 80636 | 0.020 |
Why?
|
Survival Rate | 1 | 2003 | 12725 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3518 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 1998 | 6075 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1978 | 0.020 |
Why?
|
Models, Immunological | 1 | 2011 | 513 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6310 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14605 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2011 | 964 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2021 | 11076 | 0.020 |
Why?
|
Cytokines | 2 | 2013 | 7396 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6484 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9420 | 0.020 |
Why?
|
Models, Biological | 1 | 2021 | 9469 | 0.020 |
Why?
|
DNA | 1 | 1998 | 7212 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2010 | 2078 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11528 | 0.010 |
Why?
|
Animals | 3 | 2023 | 168459 | 0.010 |
Why?
|
Phenotype | 1 | 2021 | 16591 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11903 | 0.010 |
Why?
|
Cohort Studies | 1 | 2006 | 41487 | 0.010 |
Why?
|
Cell Line | 1 | 2016 | 15601 | 0.010 |
Why?
|
Neoplasms | 1 | 2011 | 22170 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18252 | 0.010 |
Why?
|
Mice | 2 | 2021 | 81525 | 0.010 |
Why?
|
Receptors, Progesterone | 1 | 2002 | 1129 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2010 | 12341 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2002 | 21012 | 0.010 |
Why?
|
Kinetics | 1 | 2002 | 6374 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2002 | 2208 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2002 | 4915 | 0.010 |
Why?
|
Prognosis | 1 | 2002 | 29625 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2002 | 58976 | 0.000 |
Why?
|